{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:58:13Z","timestamp":1792497493761,"version":"4.5.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.autrev.2024.103644","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:11:36Z","timestamp":1726747896000},"page":"103644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inclusion body myositis: Correcting impaired mitochondrial and lysosomal autophagy as a potential therapeutic strategy"],"prefix":"10.1016","volume":"23","author":[{"given":"Stefen","family":"Brady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylviane","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103644_bb0005","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1126\/science.158.3807.1453","article-title":"Myxovirus-like structures in a case of human chronic polymyositis","volume":"158","author":"Chou","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.autrev.2024.103644_bb0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.410400407","article-title":"Inclusion body myositis: clinical and pathological boundaries","volume":"40","author":"Amato","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0025","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2024.103644_bb0030","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","article-title":"Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features","volume":"84","author":"Brady","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103644_bb0035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.nmd.2010.03.014","article-title":"International workshop on inclusion body myositis held at the Institute of Myology, Paris, on 29 May 2009","volume":"20","author":"Benveniste","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"23","key":"10.1016\/j.autrev.2024.103644_bb0040","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, the Netherlands","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318 June 2023, Hoofddorp, the Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ana.26412","article-title":"Epidemiology, survival, and clinical characteristics of inclusion body myositis","volume":"92","author":"Lindgren","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0055","doi-asserted-by":"crossref","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","article-title":"Epidemiology and natural history of inclusion body myositis: a 40-year population-based study","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0060","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<970::AID-MUS20>3.0.CO;2-I","article-title":"Prevalence of sporadic inclusion body myositis in Western Australia","volume":"23","author":"Phillips","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2024.103644_bb0065","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13023-022-02570-9","article-title":"Diagnostic delay of myositis: an integrated systematic review","volume":"17","author":"Namsrai","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2024.103644_bb0070","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00415-009-5229-9","article-title":"Detecting dysphagia in inclusion body myositis","volume":"256","author":"Cox","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","article-title":"Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials","volume":"23","author":"Cortese","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.55.2.296","article-title":"Disease progression in sporadic inclusion body myositis: observations in 78 patients","volume":"55","author":"Peng","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103644_bb0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JND-150138","article-title":"Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA","volume":"3","author":"Price","year":"2016","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2024.103644_bb0095","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/keab716","article-title":"Survival and associated comorbidities in inclusion body myositis","volume":"61","author":"Naddaf","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103644_bb0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1212\/WNL.0000000000000546","article-title":"Inclusion body myositis and chronic lymphocytic leukemia: a case series","volume":"83","author":"Beck","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0105","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2024.103644_bb0110","doi-asserted-by":"crossref","first-page":"218.e1","DOI":"10.1016\/j.neurobiolaging.2016.07.024","article-title":"Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis","volume":"47","author":"Gang","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.autrev.2024.103644_bb0115","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12931","article-title":"Mitochondrial DNA variants in inclusion body myositis characterized by deep sequencing","volume":"31","author":"Hedberg-Oldfors","year":"2021","journal-title":"Brain Pathol"},{"key":"10.1016\/j.autrev.2024.103644_bb0120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/nan.12149","article-title":"Mitochondrial and inflammatory changes in sporadic inclusion body myositis","volume":"41","author":"Rygiel","year":"2015","journal-title":"Neuropathol Appl Neurobio"},{"key":"10.1016\/j.autrev.2024.103644_bb0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneuroim.2012.05.003","article-title":"High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes","volume":"250","author":"Rojana-udomsart","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103644_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103150","article-title":"High-resolution HLA genotyping in inclusion body myositis refines 8.1 ancestral haplotype association to DRB1*03:01:01 and highlights pathogenic role of arginine-74 of DR\u03b21 chain","volume":"142","author":"Slater","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103644_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410160206","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells","volume":"16","author":"Arahata","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0140","doi-asserted-by":"crossref","first-page":"e2212","DOI":"10.1212\/WNL.0000000000201103","article-title":"Morphologic and molecular patterns of polymyositis with mitochondrial pathology and inclusion body myositis","volume":"99","author":"Kleefeld","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2680","article-title":"How citation distortions create unfounded authority: analysis of a citation network","volume":"339","author":"Greenberg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103644_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004552","article-title":"A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2024.103644_bb0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2051-5960-1-29","article-title":"Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies","volume":"1","author":"Hiniker","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.autrev.2024.103644_bb0160","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.24847","article-title":"Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis","volume":"81","author":"G\u00fcttsches","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0165","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(07)70171-0","article-title":"Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches","volume":"6","author":"Needham","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/PAI.0b013e31827d7f16","article-title":"Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy","volume":"21","author":"Das","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.autrev.2024.103644_bb0175","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2024.103644_bb0180","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archneur.1987.00520230042011","article-title":"Spectrum of inclusion body myositis","volume":"44","author":"Ringel","year":"1987","journal-title":"Arch Neurol"},{"issue":"Pt 3","key":"10.1016\/j.autrev.2024.103644_bb0185","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2024.103644_bb0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ncpneuro0261","article-title":"Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC Centre for neuromuscular diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0200","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1212\/WNL.48.4.863","article-title":"Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis","volume":"48","author":"Sekul","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0205","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","article-title":"Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis","volume":"50","author":"Cox","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103644_bb0210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/mus.24056","article-title":"Contrasting echogenicity in flexor digitorum profundus-flexor carpi ulnaris: a diagnostic ultrasound pattern in sporadic inclusion body myositis","volume":"49","author":"Noto","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2024.103644_bb0215","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ene.12899","article-title":"Intramuscular dissociation of echogenicity in the triceps surae characterizes sporadic inclusion body myositis","volume":"23","author":"Nodera","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0220","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mus.26411","article-title":"Assessing the accuracy of neuromuscular ultrasound for inclusion body myositis","volume":"59","author":"Karvelas","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2024.103644_bb0225","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ultrasmedbio.2021.04.019","article-title":"Musculoskeletal ultrasound in inclusion body myositis: a comparative study with magnetic resonance imaging","volume":"47","author":"Guimaraes","year":"2021","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.autrev.2024.103644_bb0230","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0235","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0240","doi-asserted-by":"crossref","first-page":"384","DOI":"10.55563\/clinexprheumatol\/r625rm","article-title":"Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis","volume":"40","author":"Salam","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103644_bb0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CND.0000000000000353","article-title":"Diagnostic accuracy of anti-CN1A on the diagnosis of inclusion body myositis. A hierarchical bivariate and Bayesian Meta-analysis","volume":"23","author":"Mavroudis","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2024.103644_bb0250","doi-asserted-by":"crossref","first-page":"C1291","DOI":"10.1152\/ajpcell.00531.2009","article-title":"Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy","volume":"298","author":"Sandri","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.autrev.2024.103644_bb0255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnagi.2015.00013","article-title":"Insights into muscle degeneration from heritable inclusion body myopathies","volume":"7","author":"Krause","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.autrev.2024.103644_bb0260","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.nmd.2017.05.005","article-title":"Muscle pathology in vici syndrome-a case study with a novel mutation in EPG5 and a summary of the literature","volume":"27","author":"Hedberg-Oldfors","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0265","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nmd.2014.12.010","article-title":"Mitochondrial pathology in inclusion body myositis","volume":"25","author":"Lindgren","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.molmed.2016.06.001","article-title":"Autophagy and immune senescence","volume":"22","author":"Zhang","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2024.103644_bb0275","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.redox.2014.06.004","article-title":"Variants of mitochondrial autophagy: types 1 and 2 mitophagy and micromitophagy (type 3)","volume":"2","author":"Lemasters","year":"2014","journal-title":"Redox Biol"},{"key":"10.1016\/j.autrev.2024.103644_bb0280","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.3390\/ijms22083903","article-title":"Mitophagy in human diseases","volume":"22","author":"Doblado","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103644_bb0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fcell.2020.00171","article-title":"Mammalian mitophagosome formation: a focus on the early signals and steps","volume":"8","author":"Zachari","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.autrev.2024.103644_bb0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4161\/auto.1.1.1495","article-title":"The dynamics of autophagy visualized in live cells: from autophagosome formation to fusion with endo\/lysosomes","volume":"1","author":"Bampton","year":"2005","journal-title":"Autophagy"},{"key":"10.1016\/j.autrev.2024.103644_bb0295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.abb.2007.03.034","article-title":"Selective degradation of mitochondria by mitophagy","volume":"462","author":"Kim","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.autrev.2024.103644_bb0300","doi-asserted-by":"crossref","first-page":"C308","DOI":"10.1152\/ajpcell.00056.2010","article-title":"Mitochondrial degradation by autophagy (mitophagy) in GFP-LC3 transgenic hepatocytes during nutrient deprivation","volume":"300","author":"Kim","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.autrev.2024.103644_bb0305","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/hmg\/ddt450","article-title":"Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation","volume":"23","author":"Dai","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.autrev.2024.103644_bb0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.phrs.2015.07.014","article-title":"A novel quantitative assay of mitophagy: combining high content fluorescence microscopy and mitochondrial DNA load to quantify mitophagy and identify novel pharmacological tools against pathogenic heteroplasmic mtDNA","volume":"100","author":"Diot","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2024.103644_bb0315","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4161\/auto.6.8.13426","article-title":"p62\/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both","volume":"6","author":"Narendra","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.autrev.2024.103644_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000298","article-title":"PINK1 is selectively stabilized on impaired mitochondria to activate Parkin","volume":"8","author":"Narendra","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.autrev.2024.103644_bb0325","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature07006","article-title":"Essential role for nix in autophagic maturation of erythroid cells","volume":"454","author":"Sandoval","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2024.103644_bb0330","doi-asserted-by":"crossref","first-page":"15485","DOI":"10.1038\/s41598-020-72345-4","article-title":"Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons","volume":"10","author":"Schwartzentruber","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2024.103644_bb0335","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.nmd.2016.12.009","article-title":"The role of p62\/SQSTM1 in sporadic inclusion body myositis","volume":"27","author":"Nakano","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0340","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2353\/ajpath.2010.100050","article-title":"Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers","volume":"177","author":"Nogalska","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2024.103644_bb0345","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/nan.12038","article-title":"Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres","volume":"39","author":"Cacciottolo","year":"2013","journal-title":"Neuropathol Appl Neurobio"},{"key":"10.1016\/j.autrev.2024.103644_bb0350","doi-asserted-by":"crossref","first-page":"414","DOI":"10.55563\/clinexprheumatol\/pp0oso","article-title":"The role of protein aggregation in the pathogenesis of inclusion body myositis","volume":"40","author":"Snedden","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103644_bb0355","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ymeth.2014.12.005","article-title":"Selective autophagy: xenophagy","volume":"75","author":"Bauckman","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.autrev.2024.103644_bb0360","article-title":"LC3-associated phagocytosis at a glance","volume":"132","author":"Heckmann","year":"2019","journal-title":"J Cell Sci"},{"key":"10.1016\/j.autrev.2024.103644_bb0365","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.3390\/ijms25052742","article-title":"Sporadic inclusion body myositis at the crossroads between muscle degeneration, inflammation, and aging","volume":"25","author":"Guglielmi","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.autrev.2024.103644_bb0370","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s13311-018-0658-8","article-title":"Inclusion body myositis: update on pathogenesis and treatment","volume":"15","author":"Naddaf","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2024.103644_bb0375","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40674-020-00169-4","article-title":"In pursuit of an effective treatment: the past, present and future of clinical trials in inclusion body myositis","volume":"7","author":"Snedden","year":"2021","journal-title":"Curr Treat Options Rheum"},{"key":"10.1016\/j.autrev.2024.103644_bb0380","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0385","first-page":"838","article-title":"Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients","volume":"30","author":"Dobloug","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103644_bb0390","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/BOR.0000000000000958","article-title":"Exploring challenges in the management and treatment of inclusion body myositis","volume":"35","author":"Skolka","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103644_bb0395","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103644_bb0400","doi-asserted-by":"crossref","first-page":"1020113","DOI":"10.3389\/fneur.2022.1020113","article-title":"Inclusion body myositis: update on the diagnostic and therapeutic landscape","volume":"13","author":"Naddaf","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0405","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0410","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0006-291X(03)01254-3","article-title":"Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1","volume":"307","author":"Hargitai","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2024.103644_bb0415","first-page":"8","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2024.103644_bb0420","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0425","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking Activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.autrev.2024.103644_bb0430","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0435","first-page":"96","article-title":"Efficacy and safety of Bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT","author":"Amato","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0440","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ydbio.2004.01.046","article-title":"Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis","volume":"270","author":"Amthor","year":"2004","journal-title":"Dev Biol"},{"key":"10.1016\/j.autrev.2024.103644_bb0445","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.ymthe.2017.09.002","article-title":"Unfounded claims of improved functional outcomes attributed to Follistatin gene therapy in inclusion body myositis","volume":"25","author":"Greenberg","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2024.103644_bb0450","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes as a therapeutic target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2024.103644_bb0455","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41581-023-00692-2","article-title":"The role of lysosomes in metabolic and autoimmune diseases","volume":"19","author":"Gros","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2024.103644_bb0460","doi-asserted-by":"crossref","first-page":"10675","DOI":"10.3390\/ijms241310675","article-title":"Inflammasome in skeletal muscle: NLRP3 is an inflammatory cell stress component in inclusion body myositis","volume":"24","author":"Kummer","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.autrev.2024.103644_bb0465","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tips.2023.11.005","article-title":"Pharmacological targets at the lysosomal autophagy\u2013NLRP3 inflammasome crossroads","volume":"45","author":"Bonam","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2024.103644_bb0470","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/cells10020255","article-title":"Lithium and therapeutic targeting of GSK-3","volume":"10","author":"Snitow","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2024.103644_bb0475","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.autrev.2024.103644_bb0480","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103644_bb0485","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/ene.15231","article-title":"Sirolimus leads to rapid and sustained clinical improvement of motor deficits in a patient with inclusion body myositis","volume":"29","author":"Pawlitzki","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2024.103644_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216590","article-title":"Natural compounds modulating mitophagy: implications for cancer therapy","volume":"582","author":"Cao","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.autrev.2024.103644_bb0495","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molmed.2019.03.002","article-title":"Pharmacological autophagy regulators as therapeutic agents for inflammatory bowel diseases","volume":"25","author":"Retnakumar","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2024.103644_bb0500","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41392-021-00778-y","article-title":"Targeting lysosomes in human disease: from basic research to clinical applications","volume":"6","author":"Cao","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.autrev.2024.103644_bb0505","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41589-021-00768-9","article-title":"Small molecule probes for targeting autophagy","volume":"17","author":"Whitmarsh-Everiss","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.autrev.2024.103644_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00350","article-title":"Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer\u2019s disease","volume":"21","author":"Reda","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"21","key":"10.1016\/j.autrev.2024.103644_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115732","article-title":"Chemical constituents from Macleaya cordata (Willd) R. Br. and their phenotypic functions against a Parkinson\u2019s disease patient-derived cell line","volume":"28","author":"Nguyen","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.autrev.2024.103644_bb0520","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/cells9102328","article-title":"In vivo remodeling of altered autophagy-lysosomal pathway by a Phosphopeptide in lupus","volume":"9","author":"Wang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2024.103644_bb0525","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/15548627.2015.1017179","article-title":"Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide","volume":"11","author":"Macri","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.autrev.2024.103644_bb0530","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/ard.2010.139832","article-title":"HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus","volume":"70","author":"Page","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103644_bb0535","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2012.05.016","article-title":"Peptide-based approaches to treat lupus and other autoimmune diseases","volume":"39","author":"Schall","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103644_bb0540","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaut.2018.02.005","article-title":"Rescue of autophagy and lysosome defects in salivary glands of MRL\/lpr mice by a therapeutic phosphopeptide","volume":"90","author":"Li","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103644_bb0545","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaut.2018.05.009","article-title":"An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies","volume":"92","author":"Brun","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103644_bb0550","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/cells10092468","article-title":"An autophagy modulator peptide prevents lung function decrease and corrects established inflammation in murine models of airway allergy","volume":"10","author":"Daubeuf","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2024.103644_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102814","article-title":"Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases","volume":"128","author":"Retnakumar","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103644_bb0560","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00018-022-04537-2","article-title":"Therapeutic effects of peptide P140 in a mouse periodontitis model","volume":"79","author":"Akiyama","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.autrev.2024.103644_bb0565","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.3390\/cells11233709","article-title":"The therapeutic effect of phosphopeptide P140 attenuates inflammation induced by uric acid crystals in gout arthritis mouse model","volume":"11","author":"Galv\u00e3o","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2024.103644_bb0570","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0575","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1136\/annrheumdis-2012-202460","article-title":"Lupuzor\/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial","volume":"72","author":"Zimmer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103644_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.904669","article-title":"P140 peptide leads to clearance of autoreactive lymphocytes and normalizes immune response in lupus-prone mice","volume":"13","author":"Schall","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103644_bb0585","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar2317","article-title":"Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus","volume":"9","author":"Monneaux","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103644_bb0590","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.nmd.2018.06.005","article-title":"Sensitivity and clinical utility of the anti-cytosolic 5\u2032-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center","volume":"28","author":"Felice","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103644_bb0595","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.autrev.2017.05.015","article-title":"Autophagy in neuroinflammatory diseases","volume":"16","author":"Muller","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103644_bb0600","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","article-title":"Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT","volume":"96","author":"Amato","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103644_bb0605","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103644_bb0610","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103644_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283394","article-title":"Testosterone treatment combined with exercise to improve muscle strength, physical function and quality of life in men affected by inclusion body myositis: a randomised, double-blind, placebo-controlled, crossover trial","volume":"18","author":"Connor","year":"2023","journal-title":"PloS One"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T11:10:25Z","timestamp":1731237025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":123,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1568997224001356"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103644","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inclusion body myositis: Correcting impaired mitochondrial and lysosomal autophagy as a potential therapeutic strategy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103644"}}